Adenovirus (ADV) infections after hematopoietic cell transplantation (HCT) range in severity from self-limited to fatal. We have previously reported high mortality rates in @entity2280 (+) selected @entity784 ( @entity784 ) HCT recipients using symptomatic testing and culture methods for ADV detection. We report rates and outcomes of @entity9504 in 215 adult recipients of @entity784 HCT using the CliniMACS @entity2280 (+) selection system. This was a prospective observational study of adults transplanted from March 21, 2012 through November 30, 2014 at Memorial Sloan-Kettering Cancer Center. @entity784 was performed using CliniMACS @entity2280 (+) cell selection. @entity1 were monitored for ADV by whole blood PCR assay from  +14 to  +100  days post-transplant. @entity9504 was defined as >= 1 PCR above the lower limit of quantitation. @entity9504 was defined per European Group for Blood and Marrow Transplantation guidelines. Treatment for ADV was at the clinician's discretion. Competing risk regression analyses were used to identify predictors for @entity9504 and overall survival. The median age was 55  years (range, 22 to 72); 215 @entity1 underwent @entity784 . All @entity1 received myeloablative conditioning. Eighteen @entity1 (8% of cohort) had @entity9504 at a median onset of 57  days (interquartile range [IQR], 23 to 79) and with a median viral load at first detection of 2.6 log10 copies/mL (IQR, 2.5 to 4.0). The median maximal viral load was 4.5 log10 copies/mL (IQR, 3.5 to 5.9). No significant risk factor was identified for @entity9504 by univariate analysis. Six @entity1 (3% of total cohort, 33% of viremic @entity1 ) developed @entity9504 (3 colitis, 2 @entity1310 / @entity2335 , 1 @entity55 ). @entity9504 preceded onset of @entity9504 a median of 11  days from the first positive quantitative PCR (range,  +3 to  +37) except in 1 @entity1 with @entity1310 . Overall, 12 of 18 viremic @entity1 (67%) received antiviral treatment (5 @entity7076 only, 7 brincidofovir      @entity7076 ). All @entity1 with @entity9504 were treated, and 6 @entity1 were preemptively treated for ADV. Among the 18 viremic @entity1 , 8 (44%) died during the study period, and, of those, 4 (22%) died of ADV. Early @entity9504 was infrequent (8%) among adult HCT recipients of @entity2280 (+) selected allografts. Among viremic @entity1 , rate of @entity9504 was 33% and ADV attributable mortality was 22%. Further studies are needed to assess the impact of preemptive treatment with @entity68213 on improving outcomes of @entity9504 in this @entity1 population.

XXXX in Adult @entity2280 (+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity9504 :: ('MESH:D000257', 'Disease') :: ['ADV infections', 'ADV viremia', 'ADV disease'] @entity1310 :: ('MESH:D009393', 'Disease') :: ['nephritis'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity784 :: ('MESH:D016399', 'Disease') :: ['TCD', 'T  cell-depleted'] @entity68213 :: ('MESH:C525733', 'Chemical') :: ['brincidofovir'] @entity7076 :: ('MESH:C059262', 'Chemical') :: ['cidofovir'] @entity2280 :: ('947', 'Gene') :: ['CD34'] @entity2335 :: ('MESH:D003556', 'Disease') :: ['cystitis']
@entity9504 :: (MESH:D000257,Disease) :: ['Adenovirus Viremia']
